(1). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998 Sep 12;352(9131):837-53.
https://pubmed.ncbi.nlm.nih.gov/9742976/
(2). Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
https://pubmed.ncbi.nlm.nih.gov/18784090/
(3). Effects of Intensive Glucose Lowering in Type 2 Diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. N Engl J Med 2008; 358: 2545–2559.
https://pubmed.ncbi.nlm.nih.gov/18539917/
(4). Nissen S and Wolski N. Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes. N Engl J Med 2007; 356:2457-2471.
https://pubmed.ncbi.nlm.nih.gov/17517853/
(5). U.S. Food and Drug Administration Clinical perspectives on FDA guidance for industry: diabetes mellitus: evaluating CV risk in new anti-diabetic therapies to treat T2DM. Available at https://www.fda.gov/media/71297/download
[Accessed on: 15th September 2022]
(6). Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. EMPA-REG outcome investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373:2117–2128.
https://www.nejm.org/doi/full/10.1056/NEJMoa1504720
(7).Giugliano D, Longo M, Scappaticcio L, Bellastella G, Maiorino MI, Esposito K. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol. 2021; 16;20(1):236.
https://pubmed.ncbi.nlm.nih.gov/34915880/
(8). Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC Scientific Document Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020; 41:255–323.
https://pubmed.ncbi.nlm.nih.gov/31497854/
(9). Yoshiji, S, Minamino, H, Tanaka, D, Yamane, S, Harada, N, Inagaki, N. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular and renal outcomes: A meta-analysis and meta-regression analysis. Diabetes Obes Metab. 2022; 24( 6): 1029- 1037.
https://pubmed.ncbi.nlm.nih.gov/35137511/
(10). Ghosal S, Sinha B. The cardiovascular benefits of GLP1-RAs are related to their positive effect on glycemic control: A meta-regression analysis. Diabetes Res Clin Pract. 2022; Apr; 186:109824. doi: 10.1016/j.diabres.2022.109824.
https://pubmed.ncbi.nlm.nih.gov/35271879/
(11). SAMIT GHOSAL, Binayak Sinha, Partha Kar. Reduction in “Cardiovascular death or hospitalization for heart failure” with SGLT-2 inhibitors is dependent on metabolic benefit in the form of weight loss: A meta-regression analysis. PROSPERO 2022 CRD42022321558 Available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022321558
(12). Borenstein M, Higgins JP, Hedges LV, Rothstein HR. Basics of meta-analysis: I2 is not an absolute measure of heterogeneity. Res Synth Methods. 2017 Mar;8(1):5-18.
https://pubmed.ncbi.nlm.nih.gov/28058794/
(13). Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
https://www.nejm.org/doi/full/10.1056/NEJMoa1611925
(14). Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al, Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380:347-57.
https://www.nejm.org/doi/full/10.1056/NEJMoa1812389
(15). Cnnon CP, Pratley R, Dogogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al, Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med 2020; 383:1425-1435.
https://www.nejm.org/doi/full/10.1056/NEJMoa2004967
(16). Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HLJ, Charytan DM et al, Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med 2019; 380:2295-306.
https://pubmed.ncbi.nlm.nih.gov/30990260/
(17). Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol 19, 98 (2020).
https://doi.org/10.1186/s12933-020-01071-y
(18). Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, et al. TECOS Study Group. Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin). Circulation. 2017 Sep 26;136(13):1193-1203. doi: 0.1161/CIRCULATIONAHA.117.027252.
https://pubmed.ncbi.nlm.nih.gov/28626088/
(19). Pandey A, Patel KV, Vaduganathan M, Sarma S, Haykowsky MJ, Berry JD, et al. Physical Activity, Fitness, and Obesity in Heart Failure With Preserved Ejection Fraction. JACC. Heart failure, 2018;6(12):975–982.
https://doi.org/10.1016/j.jchf.2018.09.006.
(20). Adamson C., Jhund P. S., Docherty K. F., Bělohlávek J., Chiang C. E., Diez M, et al. Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. European journal of heart failure, 2021;23(10):1662–1672.
https://doi.org/10.1002/ejhf.2308
(21). McMurray J, DeMets DL, Inzucchi SE, Køber L, Kosiborod MN, Langkilde AM, et al. DAPA-HF Committees and Investigators. The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. European journal of heart failure, 2019;21(11): 1402–1411.
https://doi.org/10.1002/ejhf.1548
(22). Tadic M, and Cuspidi C. Obesity and heart failure with preservedejection fraction: a paradox or something else? Heart failure reviews, 2019;24(3): 379–385.
https://doi.org/10.1007/s10741-018-09766-x
(23). Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, et al. I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. The New England journal of medicine, 2008;359(23): 2456–2467.
https://doi.org/10.1056/NEJMoa0805450
(24). Ather S, Chan W, Bozkurt , Aguilar, D, Ramasubbu K, Zachariah A A, Wehrens XH, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. Journal of the American College of Cardiology, 2012;59(11): 998–1005.
https://doi.org/10.1016/j.jacc.2011.11.040